Phibro Animal Health (NASDAQ:PAHC – Get Free Report) and Structure Therapeutics (NASDAQ:GPCR – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Phibro Animal Health and Structure Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Phibro Animal Health | $1.02 billion | 0.95 | $2.42 million | $0.43 | 55.47 |
| Structure Therapeutics | N/A | N/A | -$89.62 million | ($0.75) | -50.69 |
Profitability
This table compares Phibro Animal Health and Structure Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Phibro Animal Health | 1.67% | 21.44% | 5.83% |
| Structure Therapeutics | N/A | -20.12% | -19.11% |
Risk & Volatility
Phibro Animal Health has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -3.23, suggesting that its stock price is 423% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Phibro Animal Health and Structure Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Phibro Animal Health | 3 | 1 | 0 | 0 | 1.25 |
| Structure Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
Phibro Animal Health presently has a consensus price target of $14.75, indicating a potential downside of 38.16%. Structure Therapeutics has a consensus price target of $86.80, indicating a potential upside of 128.30%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Phibro Animal Health.
Summary
Phibro Animal Health beats Structure Therapeutics on 10 of the 13 factors compared between the two stocks.
About Phibro Animal Health
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
About Structure Therapeutics
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
